The PROSPER Trial: Chemotherapy-Related Endpoints in Patients with nmCRPC - Neal Shore

(Length of Presentation: 9 min)

Neal Shore, MD, FACS shares his 2018 AUA presentation on the groundbreaking PROSPER trial: chemotherapy-related endpoints in patients with nonmetastatic castration-resistant prostate cancer treated with enzalutamide. Meeting an unmet need in this Index 1 patient population with a goal of delaying time to metastasis has the potential to delay cancer-related morbidity and antineoplastic therapies and potentially prolonging overal survival.


Neal Shore, MD, FACS

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.